Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.66 USD
-0.08 (-4.32%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $1.66 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PACB 1.66 -0.08(-4.32%)
Will PACB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio (PACB) and Form Bio to Boost AAV Industry Development
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Other News for PACB
Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024
Barclays Sticks to Their Hold Rating for Pacific Biosciences (PACB)
Cathie Wood’s top and bottom performing ARKK holdings of H1
PacBio, FormBio collaborate to launch resources for AAV design, analysis